K
Kersten Borchert
Researcher at University of Rostock
Publications - 15
Citations - 380
Kersten Borchert is an academic researcher from University of Rostock. The author has contributed to research in topics: Transplantation & Panitumumab. The author has an hindex of 8, co-authored 14 publications receiving 269 citations.
Papers
More filters
Journal ArticleDOI
Forty-one recent cases of invasive zygomycosis from a global clinical registry
Maria J. G. T. Rüping,Werner J. Heinz,Anupma Jyoti Kindo,Volker Rickerts,Cornelia Lass-Flörl,Claudia Beisel,Raoul Herbrecht,Y. Roth,Gerda Silling,Andrew J. Ullmann,Kersten Borchert,Gerlinde Egerer,J Maertens,Georg Maschmeyer,Arne Simon,M. Wattad,Guido Fischer,Jörg Janne Vehreschild,Oliver A. Cornely +18 more
TL;DR: The findings indicate that the use of liposomal amphotericin B as first-line treatment for patients diagnosed with zygomycoses merits further investigation, preferably in the form of a clinical trial.
Journal ArticleDOI
Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2-positive resectable esophagogastric adenocarcinoma: Final results of the PETRARCA multicenter randomized phase II trial of the AIO.
Ralf Hofheinz,Georg Martin Haag,Thomas J. Ettrich,Kersten Borchert,Albrecht Kretzschmar,Christian Teschendorf,Gabriele Margareta Siegler,Matthias P. Ebert,Eray Goekkurt,Manfred Welslau,Rolf Mahlberg,Nils Homann,Daniel Pink,Wolf O. Bechstein,Peter Reichardt,Timo Gaiser,Disorn Sookthai,Claudia Pauligk,Thorsten Oliver Goetze,Salah-Eddin Al-Batran +19 more
TL;DR: This trial evaluates the addition of trastuzumab (tras) and pertuzumAB (per) to FLOT for resectable, esophagogastric adenocarcinoma (EGA).
Journal ArticleDOI
Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER).
Markus Moehler,Annett Maderer,Peter C. Thuss-Patience,Baruch Brenner,Johannes Meiler,Thomas J. Ettrich,R.D. Hofheinz,S.-E. Al-Batran,Arndt Vogel,Lothar Mueller,M.P. Lutz,Florian Lordick,Maria Alsina,Kersten Borchert,Richard Greil,Wolfgang Eisterer,Arno Schad,Julia Slotta-Huspenina,E. Van Cutsem,Sylvie Lorenzen +19 more
TL;DR: The trial was stopped early based on interim efficacy results triggered by the third safety analysis, and EGFR inhibition added to CF did not improve survival in unselected advanced ESCC patients.
Journal ArticleDOI
Mobilization of PBSC for allogeneic transplantation by the use of the G-CSF biosimilar XM02 in healthy donors.
Michael Schmitt,Xun Xu,Inken Hilgendorf,Catarina Schneider,Kersten Borchert,Dietrich Gläser,Mathias Freund,Anita Schmitt,Anita Schmitt +8 more
TL;DR: A comparable efficacy and safety of biosimilar G- CSF when compared with reference G-CSF is found and a safe engraftment in all patients with similar reconstitution of hematopoiesis in all hosts.
Journal ArticleDOI
1421MO Final results and subgroup analysis of the PETRARCA randomized phase II AIO trial: Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2 positive resectable esophagogastric adenocarcinoma
S-E. Al-Batran,G.M. Haag,Thomas J. Ettrich,Kersten Borchert,Albrecht Kretzschmar,Christian Teschendorf,Gabriele Margareta Siegler,MP Ebert,Eray Goekkurt,Manfred Welslau,Rolf Mahlberg,Nils Homann,Daniel Pink,Wolf O. Bechstein,Peter Reichardt,Timo Gaiser,D. Sookthai,Claudia Pauligk,Thorsten Oliver Goetze,R.D. Hofheinz +19 more
TL;DR: Oncology and Palliative Care Unit, Helios Klinikum Berlin Buch, Berlin, Germany, Institute of Pathology, University Medical Center Mannheim, Mannheim and 17 IKF, Institut für Klinische Krebsforschung IKf GmbH at Krankenhaus Nordwest, Frankfurt, Germany.